Company news
Inmune Bio Inc. (NASDAQ:INMB) news
Every Inmune Bio Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
INmune Bio Appoints Sanofi Rare-Disease Executive and Biopharma Business Development Leader to Board
September 14, 2026
INmune Bio to Present at the H.C. Wainwright Global Investment Conference
September 9, 2026
INmune Bio Advances Ebstrocel™ Toward European Marketing Authorization with EMA Regulatory Filings
August 26, 2026
INmune Bio Inc. Announces Second Quarter 2026 Results and Highlights Regulatory, Manufacturing and Clinical Progress
August 6, 2026
INmune Bio Receives R&D Rebates of Approximately $4.6 Million
July 31, 2026
INmune Bio Inc. to Report Second Quarter 2026 Financial Results and Provide Corporate Update on Thursday, August 6th
July 31, 2026
INmune Bio Establishes Scientific Advisory Board to Support Late-Stage Development and Expansion of CORDStrom™ Platform
July 30, 2026
INmune Bio Completes Commercial Manufacturing Milestone Supporting Planned Global Registration Filings for CORDStrom™ Platform
July 20, 2026
INmune Bio’s XPro1595 Prevents Brain-Injury-Induced Alzheimer's Pathology, Memory Loss, and Pain in New Peer-Reviewed Preclinical Study
July 15, 2026
INmune Bio to Present Positive Phase 2 Imaging Data for XPro in Early Alzheimer’s Disease at AAIC
July 9, 2026
INmune Bio Advances CORDStrom™ Platform Patent Application in the U.S. Following Favorable International Written Opinion
July 1, 2026
INmune Bio Inc. Achieves MHRA Approval of PIP for CORDStrom
June 26, 2026
INmune Bio Inc. Achieves MHRA Approval of PIP for CORDStrom™
June 25, 2026
INmune Bio Receives MHRA Written Alignment Supporting Planned 2026 UK Conditional Marketing Authorization Application for CORDStrom™ in RDEB
June 23, 2026
INmune Bio Reports Statistically Significant Treatment Effect on Advanced White Matter MRI Biomarker in Phase 2 MINDFuL Alzheimer's Trial
June 2, 2026
INmune Bio Publishes Phase 2 MINDFuL Trial Results in NPJ Dementia, Advancing the XPro™ Platform
May 15, 2026
INmune Bio Receives FDA Fast Track Designation for XPro1595 in Early Alzheimer's Disease
May 14, 2026
INmune Bio Named Founding Member of the American Biotech Innovation Alliance (ABIA) as U.S. Biotech Sector Navigates Strategic Inflection...
May 13, 2026
INmune Bio Inc. Announces First Quarter 2026 Results and Provides Business Update
May 7, 2026
INmune Bio and Anthony Nolan Announce Strategic Expansion of CORDStrom™ MSC Platform Collaboration to Target RDEB, Oncology, and Inflamma...
May 5, 2026
INmune Bio Inc. to Report First Quarter 2026 Financial Results and Provide Corporate Update on Thursday, May 7th
April 30, 2026
INmune Bio Inc. Announces New Preclinical Data at AACR 2026 Demonstrating INB03 (XPro1595) Overcomes Resistance and Reduces Metastases in...
April 16, 2026
INmune Bio Inc. Announces 2025 Results and Provides Business Update
March 30, 2026
INmune Bio Inc. to Report Year End 2025 Financial Results and Provide Corporate Update on Monday, March 30th.
March 24, 2026
INmune Bio’s MINDFuL Trial Featured at AD/PD 2026 Plenary as Successful Example of How to Approach Clinical Trials Targeting Inflammation...
March 19, 2026
INmune Bio to Detail XPro1595 Registrational Strategy in Upcoming Alzheimer’s Webinar
February 23, 2026
INmune Bio Announces Upcoming Webinar to Present New Clinical Data on CORDStrom™ for RDEB
February 19, 2026
INmune Bio Announces FDA Alignment on Integrated Phase 2b/3 Registration Pathway for XPro1595 in Early Alzheimer’s Disease
February 12, 2026
INmune Bio Advances CORDStrom™ Towards UK Marketing Authorization in RDEB
February 10, 2026
INmune Bio Inc Issues Shareholder Letter Reviewing 2025 Milestones and Outlining 2026 Strategic Initiatives
January 27, 2026
Peer Reviewed Study Highlights Therapeutic Potential Around Application of Stromal Cell Therapies Such as INmune Bio’s CORDStrom™ Platform
December 5, 2025
INmune Bio Reports New Phase 2 Grey Matter Imaging Data at CTAD Conference Reinforcing XPro1595’s Evidence Base in High-Inflammation Alzh...
December 1, 2025
INmune Bio Announces Two Presentations at the Upcoming 18th Annual CTAD Conference
November 18, 2025
INmune Bio Inc. Announces Third Quarter 2025 Results and Provides Business Update
October 30, 2025
INmune Bio Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on Thursday, October 30, 2025
October 23, 2025
INmune Bio to Participate in Dermatologic Rare Disease Panel at the Maxim Growth Summit 2025
October 14, 2025
INmune Bio Announces Submission of Phase 2 MINDFuL Trial Results in Alzheimer’s Disease to npj Dementia, a Nature Portfolio Journal
September 29, 2025
INmune Bio Announces Successful Completion of First Commercial Pilot-Scale Manufacturing Run of CORDStrom™ at CGT Catapult
September 15, 2025
INmune Bio Inc. Announces Second Quarter 2025 Results, Provides Business Update and Announces Management Changes
August 7, 2025
INmune Bio’s CaRe PC Trial of INKmune™ in Metastatic Castration-Resistant Prostate Cancer Meets Endpoints and Is Closed to Enrollment
August 4, 2025
INmune Bio Inc. to Report Second Quarter 2025 Financial Results and Provide Corporate Update on Thursday, August 7th
July 31, 2025
INmune Bio to Publish Video Detailing MINDFuL Trial Findings of XPro™ Presented at the Alzheimer’s Association International Conference
July 29, 2025
INmune Bio to Present Phase 2 MINDFuL Trial Findings of XPro™ at the Alzheimer’s Association International Conference
July 24, 2025
INmune Bio, Inc. Announces Closing of Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
June 30, 2025
INmune Bio Reports Key Findings from Phase 2 MINDFuL Trial of XPro™ in Early Alzheimer’s Disease
June 30, 2025
INmune Bio, Inc. Announces Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
June 27, 2025
INmune Bio Inc. to Announce Top Line Results from MINDFuL Phase 2 Trial in Early Alzheimer’s on Monday, June 30th
June 26, 2025
XPro™ Reduces Amyloid and Enhances Behavior Post Traumatic Brain Injury in an Animal Model of Alzheimer’s Disease: Supported by Departmen...
June 10, 2025
INmune Bio Inc. Announces Attendance at the 2025 RBC Capital Markets Global Healthcare Conference
May 14, 2025
INmune Bio Inc. Announces First Quarter 2025 Results and Provides Business Update
May 8, 2025